Detailed information for compound 81103
Basic information
Technical information
- TDR Targets ID: 81103
- Name: [1-hydroxy-2-(1H-imidazol-5-yl)-1-phosphonoet hyl]phosphonic acid
- MW: 272.09 | Formula: C5H10N2O7P2
-
H donors: 6
H acceptors: 8
LogP: -3.9
Rotable bonds: 4
Rule of 5 violations (Lipinski): 2 - SMILES: OC(P(=O)(O)O)(P(=O)(O)O)Cc1nc[nH]c1
- InChi: 1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)1-4-2-6-3-7-4/h2-3,8H,1H2,(H,6,7)(H2,9,10,11)(H2,12,13,14)
- InChiKey: QJYHEVLLGQDDSN-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- [1-hydroxy-2-(1H-imidazol-5-yl)-1-phosphono-ethyl]phosphonic acid
- [1-hydroxy-2-(3H-imidazol-4-yl)-1-phosphonoethyl]phosphonic acid
- [1-hydroxy-2-(3H-imidazol-4-yl)-1-phosphono-ethyl]phosphonic acid
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | farnesyl diphosphate synthase | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Plasmodium vivax | geranylgeranyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Trypanosoma cruzi | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
| Loa Loa (eye worm) | polyprenyl synthetase | 0.0123843 | 0.5 | 0.5 |
| Echinococcus granulosus | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Trichomonas vaginalis | geranylgeranyl diphosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
| Giardia lamblia | Farnesyl diphosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Mycobacterium tuberculosis | Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) | 0.0123843 | 0.5 | 0.5 |
| Trypanosoma brucei | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Toxoplasma gondii | polyprenyl synthetase superfamily protein | 0.0123843 | 0.5 | 0.5 |
| Schistosoma mansoni | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Plasmodium falciparum | geranylgeranyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
| Trypanosoma cruzi | farnesyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
| Brugia malayi | Polyprenyl synthetase family protein | 0.0123843 | 0.5 | 0.5 |
| Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Leishmania major | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Echinococcus multilocularis | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
| Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| ED50 (functional) | = 0.3 ug kg-1 | Effective dose in inhibiting osteoclastic bone resorption | ChEMBL. | 12825934 |
| ED50 (functional) | = 0.3 ug kg-1 | Effective dose after subcutaneous administration to TPTX rats for 50% reduction of hypercalcemia | ChEMBL. | 12166945 |
| ED50 (functional) | = 0.3 ug kg-1 | Effective dose in inhibiting osteoclastic bone resorption | ChEMBL. | 12825934 |
| IC50 (functional) | Inhibition of L. donovani(Amastigotes) strain MHOM/ET/67/L82 maintained in pathogen free spleen from female golden hamsters; toxic | ChEMBL. | 11300872 | |
| IC50 (functional) | = -8.958 | Negative logarithm of inhibitory concentration against bone resorption | ChEMBL. | 12825934 |
| IC50 (binding) | = -6.51 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
| IC50 (functional) | = -5.07 | Predicted pIC50 against Tryomastigotes Brucei rhodesiense. | ChEMBL. | 12086478 |
| IC50 (functional) | 0 | Inhibition of L. donovani(Amastigotes) strain MHOM/ET/67/L82 maintained in pathogen free spleen from female golden hamsters; toxic | ChEMBL. | 11300872 |
| IC50 (binding) | = 0.33 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
| IC50 (binding) | = 0.33 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
| IC50 (functional) | = 7.8 uM | Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release | ChEMBL. | 14711309 |
| IC50 (functional) | = 8.6 uM | In vitro growth inhibition of blood-stream-form Trypanosoma brucei rhodesiense Trypomastigotes | ChEMBL. | 12086478 |
| IC50 (functional) | = 8.6 uM | Inhibition of T. rhodesiense (strain STIB900) was determined using blood stream from trypomastigotes | ChEMBL. | 11300872 |
| IC50 (functional) | = 8.6 uM | Inhibition of T. rhodesiense (strain STIB900) was determined using blood stream from trypomastigotes | ChEMBL. | 11300872 |
| IC50 (functional) | = 8.6 uM | In vitro growth inhibition of blood-stream-form Trypanosoma brucei rhodesiense Trypomastigotes | ChEMBL. | 12086478 |
| IC50 (functional) | = 12 uM | Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
| IC50 (functional) | = 35 uM | Inhibition of T. cruzi Amastigotes was determined in Vero cells culture and fetal calf serum | ChEMBL. | 11300872 |
| IC50 (functional) | = 35 uM | Inhibition of T. cruzi Amastigotes was determined in Vero cells culture and fetal calf serum | ChEMBL. | 11300872 |
| IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
| IC50 (functional) | > 200 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
| IC50 (functional) | > 200 uM | Inhibition of P. falciparum (intraerythrocytic stages) strain 3D7 | ChEMBL. | 11300872 |
| IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
| IC50 (functional) | > 200 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
| IC50 (functional) | > 200 uM | Inhibition of P. falciparum (intraerythrocytic stages) strain 3D7 | ChEMBL. | 11300872 |
| IC50 (functional) | = 200 uM | Antimicrobial activity against Plasmodium falciparum | ChEMBL. | 20185316 |
| IC50 (functional) | = 200 uM | Antimicrobial activity against Entamoeba histolytica | ChEMBL. | 20185316 |
| IC50 (binding) | = 220 uM | Inhibitory activity against the human recombinant geranylgeranyl diphosphate synthase (GGPPSase). | ChEMBL. | 12014956 |
| IC50 (binding) | = 220 uM | Inhibitory activity against the human recombinant geranylgeranyl diphosphate synthase (GGPPSase). | ChEMBL. | 12014956 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli W3110 | ChEMBL. | 17149863 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli pTMV19 | ChEMBL. | 17149863 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli pTMV19 in presence of mevalonate | ChEMBL. | 17149863 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli W3110 | ChEMBL. | 17149863 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli pTMV19 | ChEMBL. | 17149863 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli pTMV19 in presence of mevalonate | ChEMBL. | 17149863 |
| Ki (binding) | = 0.03 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
| Ki (binding) | = 0.03 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
| LD50 (ADMET) | = 41 uM | 50% lethal dose for inhibition of KB cells growth | ChEMBL. | 12086478 |
| LD50 (ADMET) | > 41 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
| LD50 (ADMET) | = 41 uM | 50% lethal dose for inhibition of KB cells growth | ChEMBL. | 12086478 |
| LD50 (ADMET) | > 41 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
| Log IC50 (functional) | = 4.92 | pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
| Log IC50 (functional) | = 5.07 | Predicted pIC50 against Tryomastigotes Brucei rhodesiense. | ChEMBL. | 12086478 |
| Log IC50 (functional) | = 5.11 | pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release | ChEMBL. | 14711309 |
| Log IC50 (binding) | = 6.51 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
| Log IC50 (functional) | = 8.958 | Negative logarithm of inhibitory concentration against bone resorption | ChEMBL. | 12825934 |
| TI (ADMET) | = 5 | Therapeutic index measured as the ratio of LD50 (KB cells) to IC50 (T.b. rhodesiense) | ChEMBL. | 12086478 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Trypanosoma brucei gambiense | 11300872 | ||
| Trypanosoma brucei | ChEMBL23 | 11300872 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL301247
- PubChem: 5238184
Bibliographic References
9 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.